Genome-Wide Translatome Analysis Following Low-Dose Ketamine to Reveal Novel Targets for Antidepressant Treatment.
Synapse November 1, 2025 Oliver H Miller, Nils Grabole, Isabelle Wells et al.
Low-dose ketamine is an efficacious antidepressant for treatment-resistant unipolar and bipolar depressed patients. Major depressive disorder patients receiving a single infusion report elevated mood within 2 h, and ketamine's antidepressant effects have been observed as long as 7 days posttreatment. In light of this remarkable observation, efforts have been undertaken to "reverse-translate"...
DOI: 10.1002/syn.70033 (opens in new tab)
Full text (opens in new tab)
Ketamine antidepressant
Molecular mechanisms
Vipr2 target discovery
Targeted depression treatment